Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Thu 24:46
BRIEF-Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo Oct 21 (Reuters) - Supernus Pharmaceuticals, Inc. SUPN.O:
SUPERNUS PHARMACEUTICALS - FDA GRANTS SEVEN YEARS ORPHAN-DRUG EXCLUSIVITY FOR ONAPGO
Source text: ID:nGNX627VkX
Further company coverage: SUPN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing